Who is the new CFO of AFT Pharmaceuticals (ASX:AFP) and when do they start?

Stuart Houliston has been appointed as the new Chief Financial Officer of AFT Pharmaceuticals, with his role officially commencing on 15 June 2026. He succeeds the retiring CFO Malcolm Tubby, who will step down on 29 May 2026.

What is Stuart Houliston’s professional background prior to joining AFT Pharmaceuticals?

Houliston joins the company from Sanford, New Zealand’s largest integrated fishing and aquaculture company, which generates approximately NZ$500 million in revenue. Prior to that, he served as an Audit Director at KPMG managing a diverse portfolio of commercial businesses.

Why does this CFO transition matter for AFT Pharmaceuticals (ASX:AFP) investors?

A CFO change is a critical corporate governance event that can signal stability or strategy shifts. In this case, the transition appears orderly with an interim executive already named, reducing the risk of a leadership vacuum.

What is management’s strategy for AFT Pharmaceuticals moving forward?

Management is heavily focused on scaling operations both within local markets and internationally. According to Managing Director Dr Hartley Atkinson, the company plans to action multiple growth initiatives globally.

How might this leadership change affect the short-term share price of AFT Pharmaceuticals?

The announcement is likely to be viewed neutrally by the market in the short term, as the transition is planned and orderly. Because Houliston has a strong corporate pedigree, it mitigates potential investor anxiety regarding the departure of the long-standing CFO.

Does this news change the medium-term investment thesis for AFT Pharmaceuticals (ASX:AFP)?

The core investment thesis remains intact but receives an institutional boost. The thesis hinges on AFT's ability to commercialise its medicines globally and maintain its 29-year track record of growth.

Image for illustrative purposes only. Not a real photo.

AFT Pharmaceuticals names Stuart Houliston as CFO

Written by Mahathir BayenaPublished May 17, 2026, 11:00 PMLast Updated Jul 6, 2026, 10:11 AM

AFT Pharmaceuticals (ASX:AFP), New Zealand’s largest domestic pharmaceuticals firm, announced the appointment of Stuart Houliston as its new CFO, effective June 15.

The transition follows the upcoming retirement of current CFO Malcolm Tubby on May 29, with Simon Bosley stepped in to manage the role during the brief interim period.

Houliston joins the dual-listed pharmaceutical leader from Sanford, New Zealand’s largest integrated fishing and aquaculture company, which boasts a revenue of approximately NZ$500 million.

His extensive professional background also includes a tenure as an audit director at KPMG, where he managed a broad portfolio of commercial businesses. Houliston is a qualified chartered accountant and holds a Master of Science from Oxford University.

AFT Chair David Flacks expressed strong confidence in the new appointment, noting that Houliston’s financial expertise spanning both public markets and the accounting profession will critical support the company’s future strategy and growth initiatives.

Co-Founder and Managing Director Dr Hartley Atkinson echoed this optimism, highlighting a focus on scaling operations both locally and internationally.

Commenting on his new role, Houliston praised AFT’s 29-year track record of growth and its proven capability in developing medicines with global applications, adding that he looks forward to joining the executive team as the company’s market momentum continues to accelerate.

AFT Pharmaceuticals names Stuart Houliston as CFO

Perguntas frequentes

Ativos relacionados a notícia